Sorrento Therape
Sorrento Therapeutics, Inc., a clinical and commercial stage biopharmaceutical company, provides therapeutic solutions in the United States and internationally. It offers chimeric antigen receptor T-cell therapy, dimeric antigen receptor T-cell therapy, and antibody-drug conjugates, as well as Seprehvec, SOFUSA, RTX, and SEMDEXA. The company also develops antiviral therapies and vaccines, includi… Read more
Sorrento Therape (SRNE) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2023: 0.281x
Based on the latest financial reports, Sorrento Therape (SRNE) has a cash flow conversion efficiency ratio of 0.281x as of June 2023.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-55.66 Million) by net assets ($-197.96 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Sorrento Therape - Cash Flow Conversion Efficiency Trend (2007–2022)
This chart illustrates how Sorrento Therape's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Sorrento Therape Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Sorrento Therape ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
LAS VEGAS SANDS
BE:LCR
|
0.209x |
|
ARROWHEAD RESEARCH
BE:HDP1
|
-0.340x |
|
Fabled Copper Corp
PINK:FBCPF
|
-0.043x |
|
ARKEMA (V1S.SG)
STU:V1S
|
0.045x |
|
Kopp Glass Inc
PINK:KOGL
|
N/A |
|
Accelerate Diagnostics Inc
NASDAQ:AXDX
|
0.090x |
|
Alaska Power & Telephone Company
PINK:APTL
|
0.042x |
|
LIFECLEAN INTL AB
F:651
|
N/A |
Annual Cash Flow Conversion Efficiency for Sorrento Therape (2007–2022)
The table below shows the annual cash flow conversion efficiency of Sorrento Therape from 2007 to 2022.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2022-12-31 | $-21.67 Million | $-293.86 Million | 13.561x | +475.96% |
| 2021-12-31 | $78.13 Million | $-281.82 Million | -3.607x | -218.19% |
| 2020-12-31 | $140.73 Million | $-159.54 Million | -1.134x | +78.54% |
| 2019-12-31 | $32.76 Million | $-173.00 Million | -5.281x | -880.50% |
| 2018-12-31 | $207.50 Million | $-111.77 Million | -0.539x | -12.21% |
| 2017-12-31 | $206.61 Million | $-99.18 Million | -0.480x | +41.43% |
| 2016-12-31 | $86.50 Million | $-70.89 Million | -0.820x | -174.56% |
| 2015-12-31 | $140.94 Million | $-42.07 Million | -0.298x | -12.81% |
| 2014-12-31 | $108.71 Million | $-28.76 Million | -0.265x | -7.20% |
| 2013-12-31 | $66.81 Million | $-16.49 Million | -0.247x | +59.72% |
| 2012-12-31 | $6.20 Million | $-3.80 Million | -0.613x | +5.98% |
| 2011-12-31 | $4.21 Million | $-2.74 Million | -0.652x | -114.19% |
| 2010-12-31 | $5.08 Million | $-1.55 Million | -0.304x | -32.50% |
| 2009-12-31 | $3.20 Million | $-734.96K | -0.230x | +55.84% |
| 2008-12-31 | $392.19K | $-203.92K | -0.520x | +98.55% |
| 2007-12-31 | $18.59K | $-668.12K | -35.932x | -- |